Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

Current treatment of community-acquired pneumonia.

Liapikou A, Torres A.

Expert Opin Pharmacother. 2013 Jul;14(10):1319-32. doi: 10.1517/14656566.2013.798647. Epub 2013 May 10. Review.

PMID:
23663104
[PubMed - indexed for MEDLINE]
2.

Macrolides and pneumonia.

Brown JS, Hill AT.

Thorax. 2013 May;68(5):404-5. doi: 10.1136/thoraxjnl-2012-202425. Epub 2013 Mar 5. No abstract available.

PMID:
23462154
[PubMed - indexed for MEDLINE]
3.

An audit of inpatient management of community-acquired pneumonia in Oman: a comparison with regional clinical guidelines.

Al-Abri SS, Al-Maashani S, Memish ZA, Beeching NJ.

J Infect Public Health. 2012 Jun;5(3):250-6. doi: 10.1016/j.jiph.2012.03.002. Epub 2012 Apr 20.

PMID:
22632599
[PubMed - indexed for MEDLINE]
4.

Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.

Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M.

Clin Microbiol Infect. 2013 Apr;19(4):370-8. doi: 10.1111/j.1469-0691.2012.03838.x. Epub 2012 Apr 10. Review.

PMID:
22489673
[PubMed - indexed for MEDLINE]
5.

Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital.

Mello CF, Negra MD.

Braz J Infect Dis. 2011 May-Jun;15(3):262-7.

PMID:
21670928
[PubMed - indexed for MEDLINE]
Free Article
6.

Diagnosis and management of community-acquired pneumonia in adults.

Watkins RR, Lemonovich TL.

Am Fam Physician. 2011 Jun 1;83(11):1299-306.

PMID:
21661712
[PubMed - indexed for MEDLINE]
Free Article
7.

Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.

Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N.

J Antimicrob Chemother. 2009 May;63(5):1025-33. doi: 10.1093/jac/dkp088. Epub 2009 Mar 17.

PMID:
19293196
[PubMed - indexed for MEDLINE]
Free Article
8.

Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial.

Rubio FG, Cunha CA, Lundgren FL, Lima MP, Teixeira PJ, Oliveira JC, Golin V, Mattos WL, Mählmann HK, Moreira ED, Jardim JR, Silva RL, Silva PH.

Braz J Infect Dis. 2008 Jun;12(3):202-9.

PMID:
18833404
[PubMed - indexed for MEDLINE]
Free Article
9.

Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.

Paladino JA, Adelman MH, Schentag JJ, Iannini PB.

Pharmacoeconomics. 2007;25(8):677-83.

PMID:
17640109
[PubMed - indexed for MEDLINE]
10.

Effect of a simple educational intervention on the hospital management of community-acquired pneumonia.

Serisier DJ, Bowler SD.

Respirology. 2007 May;12(3):389-93.

PMID:
17539843
[PubMed - indexed for MEDLINE]
11.

[Evaluation of efficacy and safety of josamycin (Vilprafen) in the treatment of patients with community-acquired pneumonia].

Iakovlev SV, Aleksandrova MA, Suvorova MP, Kostina SA.

Antibiot Khimioter. 2006;51(3-4):47-8, 50-2. Russian.

PMID:
17165259
[PubMed - indexed for MEDLINE]
12.

Antibiotic treatment of community acquired pneumonia varies widely across Germany.

Kohlhammer Y, Raspe H, Marre R, Suttorp N, Welte T, Schäfer T; CAPNETZ study group.

J Infect. 2007 May;54(5):446-53. Epub 2006 Sep 26.

PMID:
17007933
[PubMed - indexed for MEDLINE]
13.

Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.

Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group.

Clin Infect Dis. 2005 Dec 15;41(12):1697-705. Epub 2005 Nov 10.

PMID:
16288390
[PubMed - indexed for MEDLINE]
Free Article
14.

The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.

Weiss K, Tillotson GS.

Chest. 2005 Aug;128(2):940-6. Review.

PMID:
16100190
[PubMed - indexed for MEDLINE]
15.

Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.

Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A, Abdulla RH, de Caprariis PJ, Knirsch CA, Amsden GW, Niederman MS, Lode H.

Treat Respir Med. 2004;3(5):329-36.

PMID:
15606222
[PubMed - indexed for MEDLINE]
16.

Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia.

Mendonça JS, Yamaguti A, Corrêa JC, Badaró R.

Braz J Infect Dis. 2004 Feb;8(1):90-100. Epub 2004 Jul 20.

PMID:
15286880
[PubMed - indexed for MEDLINE]
Free Article
17.

It's time to step up the management of community-acquired pneumonia.

Idemyor V.

J Natl Med Assoc. 2002 Mar;94(3):178-81.

PMID:
11918388
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The efficacy of an antibiotic protocol for community-acquired pneumonia.

Dobbin CJ, Duggan CJ, Barnes DJ.

Med J Aust. 2001 Apr 2;174(7):333-7.

PMID:
11346105
[PubMed - indexed for MEDLINE]
19.

[Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract].

Bogdanov MB, Chernen'kaia TV.

Antibiot Khimioter. 2000;45(10):15-8. Russian.

PMID:
11212394
[PubMed - indexed for MEDLINE]
20.

Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia.

Burgess DS, Lewis JS 2nd.

Clin Ther. 2000 Jul;22(7):872-8.

PMID:
10945513
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk